Feb 14, 2012
SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials

Nov 28, 2011
SuppreMol starts SM101 dosing in the context of SMILE study

Aug 02, 2011
SuppreMol employs Protagen biomarkers in SLE study

May 24-25, 2012
Non-Antibody Protein Production conference, Prague, Czech Republic

June 13-15, 2012
The Biopharmaceutical Conference in Europe, Cannes, France

June 18-21, 2012
BIO International Convention 2012, Boston, USA

July 8-13, 2012
FASEB Summer Research Conference "Immunoreceptors", Snowmass, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources

Prof. Peter Buckel im Video-Interview

SuppreMol GmbH is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At present, SuppreMol develops drug candidates for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis. Its lead product SM101 already is in clinical development.

The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.